You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Opioid Indicator Spray for Complex Surfaces

    SBC: Clear Scientific, LLC            Topic: CBD20AT001

    Opioids, especially synthetic opioids, are a constant threat to the safety of civilian first responders; there are now serious concerns about their use in modern chemical warfare. Fentanyl and its many analogues (carfentanil, remifentanil, lofentanil, mefentanil, sufentanil, etc.) are extremely hazardous—if ingested or inhaled, many synthetic opioids cause lethal intoxication with only a few gra ...

    STTR Phase I 2021 Department of DefenseOffice for Chemical and Biological Defense
  2. Development of selective calpain-1 inhibitors for chronic pain

    SBC: 1910 GENETICS INC.            Topic: 105

    PROJECT SUMMARY Never in the history of the United States has the unmet medical need to develop novel, non-opioid therapeutics for chronic pain been more urgent than it is today. More than 65 million US adults suffer from chronic pain, resulting in almost $635 billion in annual healthcare costs. Despite their limited efficacy, and potential for addiction, tolerance, and impaired motor performance, ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a Therapeutic Monoclonal Antibody Against EGFL6, a Mediator of Tumor Growth and Metastasis

    SBC: Tradewind BioScience            Topic: 102

    SUMMARY A diagnosis of ovarian cancer (OvCa) is especially devastating. With 22,240 diagnoses in 2018 and an estimated 14,070 deaths, OvCa has the third-highest mortality rate, leading to the fifth-highest number of cancer deaths among women in the United States. The objective of this research is to validate the anti-tumor function of humanized antibodies with the end goal of identifying and devel ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  4. VAL-0914 Decreases PAO to Protect Against Cardiac Proteinopathies

    SBC: Enable Therapeutics LLC            Topic: NHLBI

    PROJECT SUMMARY Soluble pre-amyloid oligomers (PAO) are the most potent mediators of cytotoxicity, despite common focus on autophagy as a means to clear larger misfolded protein aggregates. Specifically, PAO, rather than aggresomes, are most correlated with desmin-related cardiomyopathy (DRC) caused by an Arg120Gly missense mutation of αB-Crystallin (CryABR120G). In addition to causing DRC, emerg ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  5. Multi-stable Compliant-Mechanism-based Mattress for Bedsore Prevention

    SBC: K MEDICAL LLC            Topic: NINR

    Abstract Pressure ulcers or decubitus ulcers, more commonly known as bedsores are a huge problem affecting 2.5 million patients every year in the US and causes 60,000 deaths every year. Pressures exceeding 32 mm of Hg in the bony prominences in the back of the patient body lead to bedsores. Despite the existing low air loss mattresses, alternating pressure mattresses and the state-of-the-art air f ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  6. Developing a RPN13 inhibitor for the treatment of Quadruple Negative Breast Cancer

    SBC: Up Therapeutics LLC            Topic: 102

    Quadruple negative breast cancer (QNBC), lacking the expression of ER (estrogen receptor), PR (progesterone receptor), HER2 (human epidermal growth factor receptor 2) and AR (androgen receptor), is the breast cancer subtype with the worst prognosis, and QNBC disproportionately afflicts African Americans. It has no standard-of-care treatment targets and thus efficacious and safe treatments must be ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  7. A MEMS-Based High-Throughput Photostimulation Device with Commercial Backplane Integration

    SBC: BOULDER NONLINEAR SYSTEMS, INC.            Topic: NIMH

    Boulder Nonlinear Systems (BNS) and Prof. Rikky Muller at UC-Berkeley propose a two-phase effort to address current speed limitations in holographic photostimulation. Specifically, the proposed innovations aim to achieve streaming of high-resolution holograms at up to 10,000 frames per second (fps) to enable closed-loop optogenetic control.Optical imaging and photostimulation have emerged as compl ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  8. A New Anti-inflammatory Therapy for Ischemic Stroke

    SBC: CORNOVUS PHARMACEUTICALS INC.            Topic: NHLBI

    PROJECT SUMMARY Current therapy for ischemic stroke is limited and new treatment is needed since the mortality and morbidity of subjects with this condition remain high. Effort aimed at blocking immune cell- mediated inflammation represents a novel approach. The specific background for the proposed project is that we have identified the myeloid P2X4 receptor (P2X4R), which induces inflammation, as ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  9. Epigenetic Markers and Sustained Cytoprotection for Stroke Treatment

    SBC: ZYMO RESEARCH CORP.            Topic: NINDS

    PROJECT SUMMARY/ABSTRACT Stroke injury occurs over a long duration through pathologic changes leading to long-term neurologic dysfunction. There is an urgent need of therapeutic strategies that can provide safe and efficacious therapeutic effects to the hypoperfused brain with long-lasting endogenous neuroprotection for prevention of long-term neurologic dysfunction. Sufficient evidence has pointe ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  10. A Transparent Surgical Mask to Improve Patient/Caregiver Communication, Minimize Errors and Increase Patient Satisfaction

    SBC: FaceView Mask, LLC            Topic: NINR

    PROJECT SUMMARY Approximately 4% of people in the US are either deaf or hard of hearing, equating to more than 13 million people. Of these, approximately 12 million people over the age of 5 years have difficulty hearing normal conversation even when using a hearing aid. Hearing difficulties affect all age groups and present significant challenges in daily life. These challenges are particularly ac ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government